Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Condition:   Relapsed or Refractory Multiple Myeloma Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Pomalidomide Sponsor:   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials